AI Article Synopsis
- Carbon monoxide (CO) is being explored as a new therapy for liver cancer (HCC), but its clinical use is limited due to issues with targeting and release.
- A new CO donor called Glu-Fe(CO) has been developed, using glucose and a chemical method to create self-assembled nanomicelles that can deliver CO effectively.
- This innovative delivery system improves water solubility, allows for controlled CO release in response to glutathione, targets tumor cells using glucose, and shows promising results in killing cancer cells safely in laboratory tests and animal studies.
Article Abstract
In recent years, carbon monoxide (CO) has garnered increased attention as a novel green therapy for hepatocellular carcinoma (HCC) treatment. However, the CO donor is still limited in clinical application due to its lack of targeted ability and unstable release rate. Here, self-assembled amphiphilic nanomicelles glucose-polyethylene glycol (PEG)-lipoic acid (LA)-Fe(CO) (Glu-Fe(CO)) are first designed as a CO donor and synthesized via a chemical method, combining glucose with Fe(CO) through PEG-LA. Some advantages of this tumor-targeted Glu-Fe(CO) delivery system include (I) good water-solubility, (II) the glutathione responsive CO slow release, (III) the active tumor-targeted ability of glucose as targeted ligands, and (IV) outstanding efficacy of antitumor and safety of CO therapy of HCC both in vitro and in vivo. These findings suggest that Glu-Fe(CO) nanomicelles hold promise for enhancing antitumor therapeutic capabilities, presenting a novel tumor-targeted delivery strategy in gas therapy for HCC treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.molpharmaceut.4c00437 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!